Zobrazeno 1 - 10
of 17
pro vyhledávání: '"J.David Wallin"'
Publikováno v:
American Journal of Hypertension. 12:925-928
Nonsteroidal antiinflammatory drugs (NSAID) are frequently reported to interfere with the blood pressure lowering actions of various antihypertensive medications. We studied 17 women with arthritis and hypertension who were receiving fosinopril and H
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::824d29b2d1cee96bcc9016854bc12e06
https://doi.org/10.1016/s0895-7061(99)00075-8
https://doi.org/10.1016/s0895-7061(99)00075-8
Publikováno v:
The American Journal of Medicine. 91:S22-S28
This double-blind, double-dummy, randomized clinical trial, conducted in elderly patients with mild hypertension, compared adherence to treatment, efficacy, side effects, and quality of life during treatment with transdermal clonidine versus oral sus
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::725e16df231faea4202e1a0f7fc5bd3e
https://doi.org/10.1016/0002-9343(91)90059-7
https://doi.org/10.1016/0002-9343(91)90059-7
Publikováno v:
Journal of Urology. 143:113-115
The nonsurgical approach to unilateral ureteral obstruction due to impaction of a blood clot is described. A patient with the nephrotic syndrome secondary to minimal change disease had gross hematuria and acute renal failure following percutaneous re
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::509a30e95be3a247eb7a98e5aa81d235
https://doi.org/10.1016/s0022-5347(17)39884-1
https://doi.org/10.1016/s0022-5347(17)39884-1
Publikováno v:
Clinical Pharmacology and Therapeutics. 43:393-399
The effects of dilevalol, a new β-adrenergic blocking agent with β-agonism, on renal function were determined in two groups of patients. Patients in group 1, all with normal renal function, received either dilevalol or atenolol. Patients in group I
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fb33c2a8c07ca6d936d9cd5fabccb012
https://doi.org/10.1038/clpt.1988.49
https://doi.org/10.1038/clpt.1988.49
Autor:
Daniel J. Wilson, Herbert G. Langford, Marcia P. Poland, Eric L. Michelson, Robert F. Maronde, Nathaniel Winer, James Maloy, J.David Wallin
Publikováno v:
The American Journal of Medicine. 75:87-94
Eighty-one severely hypertensive patients were enrolled in a multicenter, double-blind, parallel group study evaluating the efficacy and safety of labetalol alone or in combination with furosemide versus methyldopa in combination with furosemide. A o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a6d17e44b1b1eb331bf4a8911017ffe0
https://doi.org/10.1016/0002-9343(83)90140-7
https://doi.org/10.1016/0002-9343(83)90140-7
Autor:
Walter Flamenbaum, Donald G. Vidt, Marcia P. Poland, Nicholas D. Vlachakis, Daniel J. Wilson, Edward D. Preis, J.David Wallin, Eric L. Michelson, Herbert G. Langford
Publikováno v:
The American Journal of Medicine. 75:95-102
The antihypertensive effects of intravenous labetalol were evaluated in 59 patients with hypertensive crises or severe hypertension in need of rapid lowering of blood pressure in a multicenter study. Patients appearing with a supine diastolic blood p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1d3596eabb0a8b0d6b38012ebfbebaae
https://doi.org/10.1016/0002-9343(83)90141-9
https://doi.org/10.1016/0002-9343(83)90141-9
Autor:
J.David Wallin, Judith Cubbon, Glen D. Bedsole, Eric L. Michelson, Marcia P. Poland, William H. Frishman, Michael Davidov, Jeffrey Gorwit, James A. Schoenberger
Publikováno v:
The American Journal of Cardiology. 63:I45-I49
Dilevalol is a new antihypertensive agent that is both a vasodilator, through its β2-agonist action, and a nonselective β antagonist. Two multicenter, double-blind studies were performed: study 1 compared dilevalol administered once-daily with eith
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ca2d619d6da370eac6258b81cc63e298
https://doi.org/10.1016/0002-9149(89)90128-8
https://doi.org/10.1016/0002-9149(89)90128-8
Autor:
J.David Wallin, William H. Frishman
Publikováno v:
The Journal of Clinical Pharmacology. 29:1057-1068
Dilevalol is the R-R' optical isomer of labetalol and differs pharmacologically from the racemic mixture in the following ways: it is seven-fold more potent as a selective beta-2 agonist; it is four times more potent as a nonselective beta antagonist
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0ab314657bee1b470ef07715aa3aaa52
https://doi.org/10.1002/j.1552-4604.1989.tb03280.x
https://doi.org/10.1002/j.1552-4604.1989.tb03280.x
Publikováno v:
The American Journal of Cardiology. 63:I75-I78
Renal function was measured in a total of 35 volunteers and patients who were given dilevalol, the R,R optical isomer of labetalol. Young normotensive volunteers (n = 6) and elderly normotensive volunteers (n = 12) received single 400- and 200-mg dos
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::db9b2d18e09a93260d672be406051b60
https://doi.org/10.1016/0002-9149(89)90134-3
https://doi.org/10.1016/0002-9149(89)90134-3
Publikováno v:
Journal of clinical pharmacology. 29(7)
Dilevalol, the R-R optical isomer of labetalol, is a nonselective beta adrenergic blocking drug with selective beta-2 agonist properties. In a double-blind, crossover study the renal function effects of dilevalol were compared to placebo in 12 normot
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f6523603e3fd545e1209b1fef1407468
https://pubmed.ncbi.nlm.nih.gov/2760254
https://pubmed.ncbi.nlm.nih.gov/2760254